Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CSPC Pharmaceutical Group ( (HK:1093) ) has shared an announcement.
CSPC Innovation Pharmaceutical Co., a subsidiary of CSPC Pharmaceutical Group, has issued an early earnings indication for 2025 showing it expects to swing from profit to a significant net loss, with net profit attributable to shareholders projected to fall by 416% to 575% year-on-year and turn negative. The company attributed the deterioration in results to sharply higher research and development spending as it accelerates its innovation pipeline, reporting substantial progress including first-time clinical trial approvals for four antibody drugs, six ADC products and one mRNA vaccine, a new indication approval for its Omalizumab injection, acceptance of a marketing application for Pertuzumab injection, and advancement of two ADC candidates into Phase III trials, developments that may weigh on near-term earnings but strengthen its longer-term competitive position in innovative therapeutics.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a major Chinese pharmaceutical company with operations spanning innovative drug research, development and manufacturing. Through its subsidiary CSPC Innovation Pharmaceutical Co., listed on Shenzhen’s ChiNext board, the group focuses on biologics, antibody drugs, antibody-drug conjugates (ADCs) and vaccines, targeting high-growth therapeutic areas that demand sustained R&D investment.
Average Trading Volume: 128,538,801
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$112.8B
See more data about 1093 stock on TipRanks’ Stock Analysis page.